RLS-0071 is ReAlta’s lead dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic-ischemic encephalopathy...
Read MorePresenting first-in-human trial data in healthy volunteers of RLS-0071, the Company’s dual action complement inhibitor and innate anti-inflammatory product candidate...
Read MoreNorfolk, VA, February 22, 2022 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer is scheduled...
Read MoreThe review article, “The EPICC Family of Anti-Inflammatory Peptides: Next Generation Peptides, Additional Mechanisms of Action and In Vivo and...
Read MoreNorfolk, VA, January 6th, 2022 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer is...
Read MoreMyeloperoxidase activity in individuals with Anti-neutrophil cytoplasmic antibodies (ANCA) can be inhibited by RLS-0071 At the 2021 Annual Conference of...
Read MoreNorfolk, VA, November 2, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer, will...
Read MoreNorfolk, VA, September 22, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer and...
Read MoreNorfolk, VA, September 22, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer and John...
Read More